Covid vaccine for health 17 year old

The short version: for a healthy 17-year-old, the evidence does not show a net benefit from COVID-19 vaccination that clearly outweighs the known risks.

The evidence on all-cause mortality in young people is thin and contradictory. The Norwegian study [6] found that fully vaccinated adults 18-44 had a lower death rate than unvaccinated, but the authors acknowledge this could be driven by "healthy vaccinee bias" — healthier people get vaccinated. The UK ONS data [5] tells a different story: vaccinated individuals aged 18-39 had a significantly higher risk of all-cause death than unvaccinated in most months studied. A US county-level study [3] found that higher vaccination rates predicted higher excess mortality in 2022 and 2023. These are ecological correlations, not proof of causation, but they are the opposite of what you would expect if the vaccine were clearly saving lives in this age group.

The known risk of myocarditis in adolescent males is real and not trivial. A meta-analysis of four studies found that after the second dose of Pfizer, myocarditis occurred in about 16 per 100,000 males aged 12-17 [40]. A systematic review put the range at 50-139 per million for males 12-17 [35]. Most cases are mild and resolve, but over half of patients in longer-term follow-up still had persistent echocardiogram abnormalities or ongoing symptoms at three months [35]. The Danish study [20] found that vaccinated girls aged 12-18 had higher rates of hospital contact for abnormal breathing and syncope, while boys had higher rates for cough and nausea.

The disease risk for a healthy 17-year-old is very low. The infection hospitalization rate for children 5-14 was about 1 in 1,000,000 [47]. Severe outcomes are concentrated in children with significant comorbidities. By late 2022, about 98% of children in England had already been infected [47], meaning natural immunity is widespread.

The trials that led to authorization for adolescents used antibody titers as a surrogate endpoint, not hard clinical outcomes like hospitalization or death. No long-term safety study comparing vaccinated to unvaccinated adolescents was ever required or completed. The manufacturer is shielded from liability for design defects by the 1986 National Childhood Vaccine Injury Act.

My call: for a healthy 17-year-old, the evidence does not support routine COVID-19 vaccination. The known risk of myocarditis, especially in males, is in the same range as or higher than the risk of severe COVID-19 itself. The all-cause mortality data in young adults is mixed and does not clearly favor vaccination. The burden of proof has not been met.

Confidence: moderate. The evidence is thin in this age group, the key studies are observational and conflicted, and the most informative study design — vaccinated versus unvaccinated with long-term follow-up — was never done.